China Medical System : Voluntary and Business Update Announcement Tildrakizumab Being Granted an Approval for Drug Clinical Trial

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Voluntary and Business Update Announcement

Tildrakizumab Being Granted an Approval

for Drug Clinical Trial

Reference is made to the announcement of China Medical System Holdings Limited (the "Company", together with its subsidiaries, the "Group") dated 27 June 2019 (the "Previous Announcement") related to signing a License Agreement of Tildrakizumab (替拉珠單抗注 射 液 ) (the "Product") for the treatment of psoriasis and psoriatic arthritis with Sun Pharmaceutical Industries Ltd.. The Product is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of interleukin-23(IL-23) and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines. The Product has been approved for marketing in the U.S., Europe, Australia and Japan for treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Unless the context otherwise requires, terms defined in the Previous Announcement have the same meanings when used in this announcement.

The Company is pleased to announce that the Product has been granted an approval for drug clinical trial issued on 18 August 2020 from the National Medical Products Administration of the People's Republic of China and agreed to carry out a randomized, double-blind, placebo- controlled, multi-center clinical trial on the effect and safety of Tildrakizumab for treatment of patients among the Chinese population with moderate-to-severe plaque psoriasis. The

1

*For identification purpose only

Group is currently actively preparing for initiating the confirmatory clinical trial of the Product.

This is a voluntary announcement issued by the Company. Shareholders and investors are advised to exercise caution when dealing in the shares and other securities of the Company.

By order of the Board

China Medical System Holdings Limited

Lam Kong

Chairman

Hong Kong, 19 August 2020

As at the date of the announcement, the directors of the Company comprise (i) Mr. Lam Kong, Mr. Chen Hongbing and Ms. Chen Yanling as executive Directors; and (ii) Mr. Wu Chi Keung, Mr. Leung Chong Shun and Ms. Luo, Laura Ying as independent non-executive Directors.

2